Alpha 2.0
Login Register
» Authors » Oneeb Majid

Oneeb Majid

Explore the profile of Oneeb Majid including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 20
Citations 204
Followers 0
Related Specialties
Pharmacology
Neurology
Psychiatry
Top 10 Co-Authors
Ziad Hussein
Jim Ferry
Leon Aarons
Antonio Laurenza
Jagadeesh Aluri
Margaret Moline
Larisa Reyderman
Bojan Lalovic
Ishani Landry
Patricia Murphy
Published In
Br J Clin Pharmacol
J Clin Pharmacol
Sleep
CPT Pharmacometrics Syst Pharmacol
Epilepsia
Affiliations
Soon will be listed here.
Recent Articles
1.
Population pharmacokinetics and exposure-response analyses of safety (ARIA-E and isolated ARIA-H) of lecanemab in subjects with early Alzheimer's disease
Majid O, Cao Y, Willis B, Hayato S, Takenaka O, Lalovic B, et al.
CPT Pharmacometrics Syst Pharmacol . 2024 Aug; 13(12):2111-2123. PMID: 39207112
Lecanemab (Leqembi®) was recently approved by health authorities in the United States, Japan, and China to treat early Alzheimer's disease (AD), including patients with mild cognitive impairment (MCI) or mild...
2.
Population pharmacokinetic-pharmacodynamic modeling of serum biomarkers as predictors of tumor dynamics following lenvatinib treatment in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC)
Majid O, Hayato S, Sreerama Reddy S, Lalovic B, Hihara T, Hoshi T, et al.
CPT Pharmacometrics Syst Pharmacol . 2024 Mar; 13(6):954-969. PMID: 38528813
Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor targeting vascular endothelial growth factor (VEGF) receptors 1-3, fibroblast growth factor (FGF) receptors 1-4, platelet-derived growth factor receptor-α (PDGFRα), KIT, and RET...
3.
Intravenous Perampanel as an Interchangeable Alternative to Oral Perampanel: A Randomized, Crossover, Phase I Pharmacokinetic and Safety Study
Hussein Z, Majid O, Boyd P, Aluri J, Ngo L, Reyderman L
Clin Pharmacol Drug Dev . 2022 May; 11(7):878-888. PMID: 35596529
Intravenous (IV) drug administration enables treatment of epilepsy when oral administration is temporarily not feasible. Perampanel is a once-daily antiseizure medication currently available as oral formulations. Study 050 (NCT03376997) was...
4.
Population Pharmacokinetics and Exposure-Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder
Lalovic B, Majid O, Aluri J, Landry I, Moline M, Hussein Z
J Clin Pharmacol . 2020 Jul; 60(12):1642-1654. PMID: 32666570
Lemborexant is a novel orexin receptor antagonist approved in the United States and Japan for the treatment of insomnia. This article describes the population pharmacokinetics (PK) of lemborexant and the...
5.
Erratum to: On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers
Vermeeren A, Jongen S, Murphy P, Moline M, Filippov G, Pinner K, et al.
Sleep . 2020 May; 43(7). PMID: 32396197
No abstract available.
6.
Adjunctive Perampanel Oral Suspension in Pediatric Patients From ≥2 to <12 Years of Age With Epilepsy: Pharmacokinetics, Safety, Tolerability, and Efficacy
Renfroe J, Mintz M, Davis R, Ferreira J, Dispoto S, Ferry J, et al.
J Child Neurol . 2019 Feb; 34(5):284-294. PMID: 30739576
Study 232, an open-label pilot study with an extension phase, evaluated the pharmacokinetics and preliminary safety/tolerability and efficacy of adjunctive perampanel oral suspension (≤0.18 mg/kg/d) in epilepsy patients aged ≥2...
7.
On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers
Vermeeren A, Jongen S, Murphy P, Moline M, Filippov G, Pinner K, et al.
Sleep . 2019 Jan; 42(4). PMID: 30597112
Study Objectives: To assess potential effects of lemborexant on next-morning driving performance in adult and elderly healthy volunteers. Methods: Randomized, double-blind, double-dummy, placebo and active-controlled, four period incomplete crossover study...
8.
Pharmacokinetics, exposure-cognition, and exposure-efficacy relationships of perampanel in adolescents with inadequately controlled partial-onset seizures
Villanueva V, Majid O, Nabangchang C, Yang H, Laurenza A, Ferry J, et al.
Epilepsy Res . 2016 Sep; 127:126-134. PMID: 27595590
Objective: To characterize, in adolescents aged 12-17, the pharmacokinetic (PK) profile of perampanel, the impact of intrinsic and extrinsic factors on PK, and the relationships between perampanel exposure and cognitive...
9.
Impact of perampanel on pharmacokinetics of concomitant antiepileptics in patients with partial-onset seizures: pooled analysis of clinical trials
Majid O, Laurenza A, Ferry J, Hussein Z
Br J Clin Pharmacol . 2016 Apr; 82(2):422-30. PMID: 27038098
Aims: To evaluate the impact of perampanel and demographics on clearance of concomitant antiepileptic drugs (AEDs), in patients with refractory partial-onset seizures. Methods: Pooled data from three Phase III clinical...
10.
The practical impact of altered dosing on perampanel plasma concentrations: pharmacokinetic modeling from clinical studies
Gidal B, Majid O, Ferry J, Hussein Z, Yang H, Zhu J, et al.
Epilepsy Behav . 2014 May; 35:6-12. PMID: 24785428
Rationale: Perampanel is a selective AMPA receptor antagonist approved for adjunctive therapy in patients with refractory partial-onset seizures. Perampanel is metabolized primarily via CYP3A4, yet it has a relatively long...